{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:29Z","timestamp":1792931969692,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800174"],"award-info":[{"award-number":["81800174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770184"],"award-info":[{"award-number":["81770184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970143"],"award-info":[{"award-number":["81970143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a hematological malignancy with high incidence and recurrence rates. Gene expression profiling has revealed that transcriptional overexpression of glioma\u2010associated oncogene 1 (GLI1), a vital gene in the Hedgehog (Hh) signaling pathway, occurs in poor-prognosis AML, and high levels of phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1) and AKT3 predict shorter overall survival in AML patients. In this study, we discovered that GLI1 overexpression promotes cell proliferation and reduces chemotherapy sensitivity in AML cells while knocking down GLI1 has the opposite effect. Moreover, GLI1 promoted cell cycle progression and led to elevated protein levels of cyclins and cyclin-dependent kinases (CDKs) in AML cells. By luciferase assays and co-immunoprecipitation, we demonstrated that the PI3K\/AKT pathway is directly activated by GLI1. GLI1 overexpression significantly accelerates tumor growth and upregulated p-AKT, CDK4, and cyclinD3 in vivo. Notably, the GLI1 inhibitor GANT61 and the CDK4\/6 inhibitor PD 0332991 had synergistic effects in promoting Ara-c sensitivity in AML cell lines and patient samples. Collectively, our data demonstrate that GLI1 reduces drug sensitivity by regulating cell cycle through the PI3K\/AKT\/GSK3\/CDK pathway, providing a new perspective for involving GLI1 and CDK4\/6 inhibitors in relapsed\/refractory (RR) patient treatment.<\/jats:p>","DOI":"10.1038\/s41419-021-03504-2","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T10:06:54Z","timestamp":1614766014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia"],"prefix":"10.1038","volume":"12","author":[{"given":"Cheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-8888","authenticated-orcid":false,"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"3504_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med 17, 1086\u20131093 (2011).","journal-title":"Nat. Med"},{"key":"3504_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/157488810791824485","volume":"5","author":"X Thomas","year":"2010","unstructured":"Thomas, X. & Cannas, G. Leukemia stem cells and new strategies to overcome resistance to therapy. Curr. Stem Cell Res Ther. 5, 277\u2013286 (2010).","journal-title":"Curr. Stem Cell Res Ther."},{"key":"3504_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/nature07284","volume":"455","author":"Z Wang","year":"2008","unstructured":"Wang, Z. et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455, 1205\u20131209 (2008).","journal-title":"Nature"},{"key":"3504_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-020-00935-w","volume":"13","author":"Y Jia","year":"2020","unstructured":"Jia, Y. et al. Roles of hsa-miR-12462 and SLC9A1 in acute myeloid leukemia. J. Hematol. Oncol. 13, 101 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"3504_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park, S. et al. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95, 819\u2013828 (2010).","journal-title":"Haematologica"},{"key":"3504_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-017-0163-4","volume":"15","author":"F Aberger","year":"2017","unstructured":"Aberger, F., Hutterer, E., Sternberg, C., Del Burgo, P. J. & Hartmann, T. N. Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog\/GLI signaling. Cell Commun. Signal 15, 8 (2017).","journal-title":"Cell Commun. Signal"},{"key":"3504_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","volume":"111","author":"J Tamburini","year":"2008","unstructured":"Tamburini, J. et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379\u2013382 (2008).","journal-title":"Blood"},{"key":"3504_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3324\/haematol.2009.010785","volume":"95","author":"N Chapuis","year":"2010","unstructured":"Chapuis, N. et al. Autocrine IGF-1\/IGF-1R signaling is responsible for constitutive PI3K\/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95, 415\u2013423 (2010).","journal-title":"Haematologica"},{"key":"3504_CR9","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1159\/000443075","volume":"38","author":"B Long","year":"2016","unstructured":"Long, B. et al. Targeting GLI1 suppresses cell growth and enhances chemosensitivity in CD34+ enriched acute myeloid leukemia progenitor cells. Cell Physiol. Biochem 38, 1288\u20131302 (2016).","journal-title":"Cell Physiol. Biochem"},{"key":"3504_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.embor.7400959","volume":"8","author":"DJ Robbins","year":"2007","unstructured":"Robbins, D. J. & Hebrok, M. Hedgehogs: la dolce vita. Workshop on Hedgehog-Gli signaling in cancer and stem cells. EMBO Rep. 8, 451\u2013455 (2007).","journal-title":"EMBO Rep."},{"key":"3504_CR11","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.2147\/OTT.S216628","volume":"12","author":"K Huang","year":"2019","unstructured":"Huang, K. et al. Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia. Onco Targets Ther. 12, 7477\u20137488 (2019).","journal-title":"Onco Targets Ther."},{"key":"3504_CR12","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1038\/onc.2011.195","volume":"30","author":"RR Singh","year":"2011","unstructured":"Singh, R. R. et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30, 4874\u20134886 (2011).","journal-title":"Oncogene"},{"key":"3504_CR13","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1038\/onc.2010.375","volume":"29","author":"KC Queiroz","year":"2010","unstructured":"Queiroz, K. C. et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29, 6314\u20136322 (2010).","journal-title":"Oncogene"},{"key":"3504_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","volume":"14","author":"C Dierks","year":"2008","unstructured":"Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238\u2013249 (2008).","journal-title":"Cancer Cell"},{"key":"3504_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41388-018-0431-9","volume":"38","author":"BW Lau","year":"2019","unstructured":"Lau, B. W. et al. Hedgehog\/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. Oncogene 38, 687\u2013698 (2019).","journal-title":"Oncogene"},{"key":"3504_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0294-z","volume":"31","author":"YY Li","year":"2014","unstructured":"Li, Y. Y. et al. Association between polymorphism of GLI1 gene SNP rs2228226 and chronic lymphocytic leukemia in Chinese population. Med Oncol. 31, 294 (2014).","journal-title":"Med Oncol."},{"key":"3504_CR17","doi-asserted-by":"publisher","first-page":"291ra296","DOI":"10.1126\/scitranslmed.aaa5731","volume":"7","author":"Y Lim","year":"2015","unstructured":"Lim, Y. et al. Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Sci. Transl. Med 7, 291ra296 (2015).","journal-title":"Sci. Transl. Med"},{"key":"3504_CR18","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","volume":"2","author":"G Martinelli","year":"2015","unstructured":"Martinelli, G. et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2, e339\u2013e346 (2015).","journal-title":"Lancet Haematol."},{"key":"3504_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.leukres.2019.03.008","volume":"81","author":"DA Sallman","year":"2019","unstructured":"Sallman, D. A. et al. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk. Res 81, 56\u201361 (2019).","journal-title":"Leuk. Res"},{"key":"3504_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046853","volume":"7","author":"S Zhang","year":"2012","unstructured":"Zhang, S. et al. Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS ONE 7, e46853 (2012).","journal-title":"PLoS ONE"},{"key":"3504_CR21","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.2174\/092986711796011201","volume":"18","author":"AM Martelli","year":"2011","unstructured":"Martelli, A. M. et al. Targeting the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin signaling network in cancer stem cells. Curr. Med Chem. 18, 2715\u20132726 (2011).","journal-title":"Curr. Med Chem."},{"key":"3504_CR22","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/0008-5472.CAN-04-0174","volume":"64","author":"YH Min","year":"2004","unstructured":"Min, Y. H. et al. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 64, 5225\u20135231 (2004).","journal-title":"Cancer Res"},{"key":"3504_CR23","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","volume":"108","author":"SM Kornblau","year":"2006","unstructured":"Kornblau, S. M. et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108, 2358\u20132365 (2006).","journal-title":"Blood"},{"key":"3504_CR24","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","volume":"102","author":"Q Xu","year":"2003","unstructured":"Xu, Q., Simpson, S. E., Scialla, T. J., Bagg, A. & Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102, 972\u2013980 (2003).","journal-title":"Blood"},{"key":"3504_CR25","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/sj.leu.2403402","volume":"18","author":"Y Kubota","year":"2004","unstructured":"Kubota, Y., Ohnishi, H., Kitanaka, A., Ishida, T. & Tanaka, T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18, 1438\u20131440 (2004).","journal-title":"Leukemia"},{"key":"3504_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.canlet.2015.11.006","volume":"370","author":"J Zhou","year":"2016","unstructured":"Zhou, J. et al. Non-canonical GLI1\/2 activation by PI3K\/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. Cancer Lett. 370, 313\u2013323 (2016).","journal-title":"Cancer Lett."},{"key":"3504_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0368-y","volume":"32","author":"Z Ke","year":"2015","unstructured":"Ke, Z., Caiping, S., Qing, Z. & Xiaojing, W. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K\/AKT pathway. Med. Oncol. 32, 368 (2015).","journal-title":"Med. Oncol."},{"key":"3504_CR28","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1158\/0008-5472.CAN-12-1248","volume":"72","author":"B Ramaswamy","year":"2012","unstructured":"Ramaswamy, B. et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K\/AKT pathway. Cancer Res. 72, 5048\u20135059 (2012).","journal-title":"Cancer Res."},{"key":"3504_CR29","doi-asserted-by":"publisher","first-page":"33004","DOI":"10.18632\/oncotarget.8844","volume":"7","author":"X Li","year":"2016","unstructured":"Li, X. et al. Gli-1\/PI3K\/AKT\/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells. Oncotarget 7, 33004\u201333015 (2016).","journal-title":"Oncotarget"},{"key":"3504_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep40361","volume":"7","author":"H Liang","year":"2017","unstructured":"Liang, H. et al. Targeting the PI3K\/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells. Sci. Rep. 7, 40361 (2017).","journal-title":"Sci. Rep."},{"key":"3504_CR31","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/0008-5472.CAN-14-2486","volume":"75","author":"C Yang","year":"2015","unstructured":"Yang, C. et al. CDK4\/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity. Cancer Res. 75, 1838\u20131845 (2015).","journal-title":"Cancer Res."},{"key":"3504_CR32","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1080\/15384101.2019.1644913","volume":"18","author":"F Sun","year":"2019","unstructured":"Sun, F. et al. Ara-c induces cell cycle G1\/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4\/cyclin D1. Cell Cycle 18, 2293\u20132306 (2019).","journal-title":"Cell Cycle"},{"key":"3504_CR33","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/0008-5472.CAN-14-0573","volume":"75","author":"N Javidi-Sharifi","year":"2015","unstructured":"Javidi-Sharifi, N. et al. Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 75, 880\u2013891 (2015).","journal-title":"Cancer Res."},{"key":"3504_CR34","doi-asserted-by":"publisher","first-page":"63995","DOI":"10.18632\/oncotarget.11745","volume":"7","author":"X Sun","year":"2016","unstructured":"Sun, X., Bao, J., You, Z., Chen, X. & Cui, J. Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination. Oncotarget 7, 63995\u201364006 (2016).","journal-title":"Oncotarget"},{"key":"3504_CR35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione, R. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146, 392\u2013400 (2014). e393.","journal-title":"Gastroenterology"},{"key":"3504_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1568009611313030009","volume":"13","author":"M Santoni","year":"2013","unstructured":"Santoni, M. et al. Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming? Curr. Cancer Drug Targets 13, 313\u2013325 (2013).","journal-title":"Curr. Cancer Drug Targets"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03504-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:33:10Z","timestamp":1669919590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03504-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["3504"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03504-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study conforms to the guidelines approved by the Ethics Committee of Xiangya Hospital, Central South University. Signed informed consent was obtained from all participants or their guardians. Animal experiments were conducted according to the international conventions on laboratory animal ethics and relevant national regulations, and all efforts were made to minimize the suffering of the animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"231"}}